Jose Sandoval Sus, MD

Articles by Jose Sandoval Sus, MD

Spotlighting Emergent CAR T-Cell Therapy in High-Risk B-Cell Lymphomas

August 8th 2025

Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.

Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.

Identifying Limitations to CAR T-Cell Therapies in Large B-Cell Lymphoma

ByJose Sandoval Sus, MD

August 6th 2025

Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.

Latest Updated Articles

Spotlighting Emergent CAR T-Cell Therapy in High-Risk B-Cell Lymphomas
Published: August 8th 2025 | Updated:

Jose Sandoval Sus, MD

Articles by Jose Sandoval Sus, MD

Spotlighting Emergent CAR T-Cell Therapy in High-Risk B-Cell Lymphomas

Identifying Limitations to CAR T-Cell Therapies in Large B-Cell Lymphoma

Latest Updated Articles

Trending on CancerNetwork

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC

Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL

Short-Course Radiation May Be Feasible in Older Rectal Cancer Population